Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Source: View publication →
In patients with completely resected stage IB-IIIA NSCLC who had completed adjuvant platinum-based chemotherapy, the addition of one year of adjuvant atezolizumab significantly improved disease-free survival, with the most pronounced benefit seen in patients with PD-L1 expressing tumors.
Key Findings
Study Design
Study Limitations
Clinical Significance
IMpower010 was a landmark, paradigm-shifting trial that established immune checkpoint inhibition as a new standard of care in the adjuvant setting for resectable NSCLC. Based on these primary results, adjuvant atezolizumab was approved for patients with stage II-IIIA NSCLC whose tumors express PD-L1 ≥1% (with varying regional thresholds, such as ≥50% in Europe) following surgery and platinum-based chemotherapy, fundamentally changing early-stage lung cancer treatment pathways.
Historical Context
Historically, surgery followed by adjuvant platinum-based chemotherapy was the standard of care for early-stage (II-IIIA) NSCLC. However, the survival benefit conferred by chemotherapy was uninspiring, yielding only a 5.4% absolute improvement in 5-year overall survival according to the classic LACE meta-analysis. Following the revolution of immunotherapy in metastatic NSCLC and the PACIFIC trial's success in locally advanced, unresectable disease, IMpower010 was the first phase 3 trial to successfully demonstrate that an immune checkpoint inhibitor could significantly prolong disease-free survival when administered after curative-intent surgery and adjuvant chemotherapy.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of atezolizumab differ from traditional cytotoxic chemotherapy, and what is the biological rationale for administering immunotherapy after chemotherapy in the adjuvant setting for NSCLC?
Key Response
Atezolizumab is a monoclonal antibody that blocks PD-L1, preventing it from binding to PD-1 and B7.1, thus reversing T-cell exhaustion. Chemotherapy causes tumor cell death and neoantigen release, which primes the immune system. Administering atezolizumab afterward capitalizes on this primed state to eliminate micrometastatic disease and improve disease-free survival.
A patient with completely resected stage IIB NSCLC completes 4 cycles of adjuvant cisplatin and pemetrexed. Their tumor shows a PD-L1 expression of 5 percent. Based on the IMpower010 trial, how should you counsel this patient regarding the expected benefit and potential risks of adding 1 year of adjuvant atezolizumab?
Key Response
Based on IMpower010, this patient falls into the subgroup (Stage II-IIIA, PD-L1 greater than or equal to 1 percent) that derived significant disease-free survival benefit. Counseling must balance the reduced risk of recurrence against the risk of immune-related adverse events, such as pneumonitis or endocrinopathies, which are fundamentally different from the myelosuppression and neuropathy they experienced with chemotherapy.
The IMpower010 trial allowed patients with EGFR mutations or ALK translocations to enroll. How did these specific genomic subgroups perform in terms of disease-free survival with adjuvant atezolizumab, and how does this influence systemic therapy sequencing in oncogene-driven early-stage NSCLC?
Key Response
Subgroup analyses in IMpower010 showed that patients with EGFR or ALK alterations did not derive a clear DFS benefit from adjuvant atezolizumab. Oncogene-addicted tumors typically have an immunosuppressive microenvironment and respond poorly to single-agent checkpoint inhibitors. For EGFR-mutated patients, the ADAURA trial established adjuvant osimertinib as the standard of care, making targeted therapy the priority over immunotherapy in this subgroup.
IMpower010 demonstrated a clear DFS advantage, but early Overall Survival data was immature. As an attending, how do you balance the robust DFS benefit against the potential for chronic immune-related toxicities when discussing adjuvant atezolizumab with a patient whose tumor has a PD-L1 of 1 to 49 percent, a group where the benefit is less pronounced?
Key Response
While DFS is a valid surrogate endpoint, curing a patient who was already potentially cured by surgery and chemotherapy, but leaving them with lifelong endocrinopathy (e.g., adrenal insufficiency), requires careful shared decision-making. The magnitude of benefit in IMpower010 was heavily driven by the PD-L1 greater than 50 percent subgroup, requiring attendings to critically weigh absolute risk reduction versus permanent toxicity in intermediate expressers.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The IMpower010 trial utilized a hierarchical statistical testing strategy, testing DFS first in the stage II-IIIA PD-L1 TC greater than or equal to 1 percent population, then all randomized stage II-IIIA, and finally the ITT stage IB-IIIA population. What are the methodological advantages and limitations of this gatekeeping approach?
Key Response
Hierarchical testing controls the family-wise type I error rate across multiple populations. However, if a higher-tier test fails, formal statistical significance cannot be claimed for subsequent tiers. In IMpower010, the profound benefit in the high PD-L1 group drove the success of the broader populations, complicating the extraction of isolated hazard ratios for the PD-L1 negative subgroup without relying on exploratory interaction tests.
IMpower010 was an open-label trial comparing atezolizumab to best supportive care. As a reviewer, how might the lack of a placebo control introduce assessment bias into the investigator-assessed Disease-Free Survival endpoint, and what trial design modifications could have mitigated this threat to validity?
Key Response
Open-label designs are prone to assessment bias, particularly for borderline radiological findings. Investigators knowing a patient is on an active drug might subconsciously delay declaring progression, or conversely, overcall progression in the control arm. A placebo-controlled design with blinded independent central review (BICR) mitigates this bias and is the gold standard for subjective endpoints like DFS.
Given the IMpower010 results, how should clinical guidelines integrate adjuvant atezolizumab into the treatment algorithm for completely resected stage II-IIIA NSCLC, specifically considering the rise of neoadjuvant chemoimmunotherapy such as the CheckMate 816 regimen?
Key Response
IMpower010 provides level 1 evidence for adjuvant atezolizumab in stage II-IIIA NSCLC with PD-L1 greater than or equal to 1 percent, leading to its category 1 recommendation in NCCN guidelines. However, guidelines must now emphasize multidisciplinary tumor board review prior to surgery to decide between neoadjuvant approaches (CheckMate 816) versus upfront surgery followed by adjuvant therapy, positioning atezolizumab primarily for patients who proceed straight to surgery without neoadjuvant immunotherapy.
Clinical Landscape
Noteworthy Related Trials
ADAURA Trial
Tested
Osimertinib 80mg daily for up to 3 years
Population
Completely resected stage IB-IIIA EGFR-mutated NSCLC
Comparator
Placebo
Endpoint
Disease-free survival (DFS) in stage II-IIIA patients
PEARLS/KEYNOTE-091 Trial
Tested
Pembrolizumab 200mg every 3 weeks
Population
Completely resected stage IB-IIIA NSCLC
Comparator
Placebo
Endpoint
Disease-free survival (DFS)
CheckMate 816 Trial
Tested
Neoadjuvant nivolumab plus platinum-based chemotherapy
Population
Resectable stage IB-IIIA NSCLC
Comparator
Platinum-based chemotherapy alone
Endpoint
Event-free survival (EFS) and pathological complete response (pCR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis